Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Goodwill (2016 - 2026)

Anika Therapeutics has reported Goodwill over the past 17 years, most recently at $7.9 million for Q1 2026.

  • Quarterly Goodwill rose 6.32% to $7.9 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $7.9 million through Mar 2026, up 6.32% year-over-year, with the annual reading at $8.1 million for FY2025, 13.04% up from the prior year.
  • Goodwill was $7.9 million for Q1 2026 at Anika Therapeutics, down from $8.1 million in the prior quarter.
  • Over five years, Goodwill peaked at $8.1 million in Q2 2025 and troughed at $6.7 million in Q3 2022.
  • The 5-year median for Goodwill is $7.5 million (2023), against an average of $7.5 million.
  • Year-over-year, Goodwill decreased 15.46% in 2022 and then rose 13.04% in 2025.
  • A 5-year view of Goodwill shows it stood at $7.3 million in 2022, then grew by 3.16% to $7.6 million in 2023, then dropped by 5.89% to $7.1 million in 2024, then increased by 13.04% to $8.1 million in 2025, then dropped by 2.01% to $7.9 million in 2026.
  • Per Business Quant, the three most recent readings for ANIK's Goodwill are $7.9 million (Q1 2026), $8.1 million (Q4 2025), and $8.1 million (Q3 2025).